- About
- Projects
- Research
- Addressing Unmet Need Within the Animal and Veterinary Industries
- Antimicrobial Use Data in Food Animals
- Expanded Access Navigator
- Fellowship
- Food & Nutrition
- FDA Operational Evaluation
- FDA Patient Listening Sessions
- Improving Access to Publicly Available FDA Information
- Improving Understanding of the FDA and FDA-Regulated Products
- Substance Use Disorders
- COVID-19 Hub
- Regulatory Science Accelerator
- News and Events
- eRequest
Past Events
The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, hosted a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest."
The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a public webinar as part of a series of webinars for FDA-issued guidance related to real-world evidence (RWE).
The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.
Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the U.S. Food and Drug Administration.
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
-
Advancing Psychedelic Clinical Study Design
Virtual Public Meeting
Day 1: January 31, 2024 | 10am-2pm (eastern)
Front-of-Package Nutrition Labeling
Virtual Public Meeting
Integrating Clinical Studies Into Health Care Delivery:
Post-Market Evidence Generation for Medical Products
Virtual Public Meeting
Strategies for Improving Public Understanding of FDA-Regulated Products
Virtual Public Meeting